These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17369583)

  • 21. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
    Judson IR
    J Clin Oncol; 2008 Nov; 26(33):5322-5. PubMed ID: 18955449
    [No Abstract]   [Full Text] [Related]  

  • 22. [Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].
    Wang CM; Shi YQ; Fu H; Zhao GF; Zhou Y; Du CY; Ye YW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 May; 13(5):371-4. PubMed ID: 20499309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current management of GIST.
    Blanke C
    Clin Adv Hematol Oncol; 2004 May; 2(5):280, 283. PubMed ID: 17682286
    [No Abstract]   [Full Text] [Related]  

  • 24. Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.
    Grabellus F; Ebeling P; Worm K; Sheu SY; Antoch G; Frilling A; Schmid KW
    Gut; 2007 Jul; 56(7):1025-6. PubMed ID: 17566038
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.
    Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P
    Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
    Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
    J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.
    Benjamin RS; Debiec-Rychter M; Le Cesne A; Sleijfer S; Demetri GD; Joensuu H; Schöffski P; Poveda A
    Semin Oncol; 2009 Aug; 36(4):302-11. PubMed ID: 19664491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K; Matsumoto T; Hirota S
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.
    Wardelmann E; Thomas N; Merkelbach-Bruse S; Pauls K; Speidel N; Büttner R; Bihl H; Leutner CC; Heinicke T; Hohenberger P
    Lancet Oncol; 2005 Apr; 6(4):249-51. PubMed ID: 15811621
    [No Abstract]   [Full Text] [Related]  

  • 30. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.
    Loughrey MB; Waring PM; Dobrovic A; Demetri G; Kovalenko S; McArthur G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6205-6; author reply 6206-7. PubMed ID: 17062700
    [No Abstract]   [Full Text] [Related]  

  • 31. Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors.
    Kim TW; Ryu MH; Lee H; Sym SJ; Lee JL; Chang HM; Park YS; Lee KH; Kang WK; Shin DB; Bang YJ; Lee JS; Kang YK
    Oncologist; 2009 May; 14(5):540-7. PubMed ID: 19411681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation.
    Wakai T; Kanda T; Hirota S; Ohashi A; Shirai Y; Hatakeyama K
    Br J Cancer; 2004 Jun; 90(11):2059-61. PubMed ID: 15150562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.
    Floris G; Debiec-Rychter M; Sciot R; Stefan C; Fieuws S; Machiels K; Atadja P; Wozniak A; Faa G; Schöffski P
    Clin Cancer Res; 2009 Jun; 15(12):4066-76. PubMed ID: 19509176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
    Cassier PA; Dufresne A; Arifi S; El Sayadi H; Labidi I; Ray-Coquard I; Tabone S; Méeus P; Ranchère D; Sunyach MP; Decouvelaere AV; Alberti L; Blay JY
    Expert Opin Pharmacother; 2008 May; 9(7):1211-22. PubMed ID: 18422477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. That's the "GIST" of it: use of adjuvant imatinib after resection of a primary GI stromal tumor.
    Tap WD; Schwartz GK
    J Clin Oncol; 2014 May; 32(15):1543-6. PubMed ID: 24638004
    [No Abstract]   [Full Text] [Related]  

  • 37. Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors?
    Yoon SS; Tanabe KK
    Ann Surg Oncol; 2007 Jun; 14(6):1784-6. PubMed ID: 17356951
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
    Bertucci F; Goncalves A; Monges G; Madroszyk A; Guiramand J; Moutardier V; Noguchi T; Dubreuil P; Sobol H
    Oncol Rep; 2006 Jul; 16(1):97-101. PubMed ID: 16786129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
    Baruchel S; Sharp JR; Bartels U; Hukin J; Odame I; Portwine C; Strother D; Fryer C; Halton J; Egorin MJ; Reis RM; Martinho O; Stempak D; Hawkins C; Gammon J; Bouffet E
    Eur J Cancer; 2009 Sep; 45(13):2352-9. PubMed ID: 19505817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.